SOM Biotech

SOM Biotech secures clear registrational path for SOM3355 in Huntington’s disease after FDA End‑of‑Phase 2 Meeting

20 October 2025 -- Barcelona, Spain -- SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final report on the End-of-Phase 2 Meeting held with the US Food and Drug Administration (FDA) on September 19, 2025. The Agency...
Baldiri Reixac, 4 (08028) Barcelona, Spain

+34 934 020 150